Integrating New Therapies Into the Management of Relapsed/Refractory Myeloma: Experts Address the Paradox of Choice

Download All
Hear from experts how the latest data from ASCO 2021 inform therapeutic strategies for patients with R/R MM and how to evaluate novel combination therapeutic regimens. Review their insights in clinical commentaries, slides, a podcast, and an on-demand webcast from a live CCO webinar.
Paul G. Richardson, MD
Program Director
Paul G. Richardson, MD
person default
Nina Shah, MD
Peter M. Voorhees, MD

On-Demand Webcast

Watch this on-demand webcast from a live webinar where 3 experts discuss the latest data for the management of patients with relapsed or refractory myeloma, including new data from ASCO 2021.

Paul G. Richardson, MD
Program Director
person default Nina Shah, MD Peter M. Voorhees, MD
Physicians: maximum of 1.75 AMA PRA Category 1 Credits Released: July 9, 2021 Expired: July 8, 2022

Downloadable Slidesets

Download this slideset based on the content from a live-stream CCO series from Paul G. Richardson on treatment options for patients with relapsed/refractory multiple myeloma who have relapsed after first-line therapy.

Paul G. Richardson, MD
Program Director
Released: June 23, 2021

Download this slideset based on the content from a live-stream CCO series from Peter M. Voorhees, MD on treatment options for patients with relapsed/refractory multiple myeloma who have relapsed after multiple lines of therapy.

Peter M. Voorhees, MD Released: June 24, 2021

Download this slideset based on the content from a live-stream CCO series from Nina Shah, MD on novel therapies under investigation for patients with relapsed/refractory multiple myeloma, including CAR T-cell therapies, bispecific antibodies, antibody drug conjugates, and CELMoDs.

person default Nina Shah, MD Released: June 24, 2021

Gain key clinical insights fast, with this short summary slideset from CCO on key considerations for optimal treatment selection for patients with relapsed/refractory myeloma.

Paul G. Richardson, MD
Program Director
person default Nina Shah, MD Peter M. Voorhees, MD
Released: June 25, 2021

ClinicalThought

The treatment landscape for multiple myeloma is rapidly evolving. Read how expert faculty choose and sequence therapy for patients with relapsed/refractory multiple myeloma to improve patient outcomes.

Paul G. Richardson, MD
Program Director
person default Nina Shah, MD Peter M. Voorhees, MD
Released: August 19, 2021

Podcast

Listen to Paul G. Richardson, MD; Nina Shah, MD; and Peter M. Voorhees, MD, as they answer audience questions from a live webinar about how to best use the plethora of active agents and regimens now available for patients with advanced multiple myeloma.

Paul G. Richardson, MD
Program Director
person default Nina Shah, MD Peter M. Voorhees, MD
Released: August 24, 2021

Download this short summary of key takeaways from a podcast on managing patients with R/R MM including expert recommendations on selecting optimal therapy.

Paul G. Richardson, MD person default Nina Shah, MD Peter M. Voorhees, MD Released: August 25, 2021
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Bristol-Myers Squibb
GlaxoSmithKline
Karyopharm
Oncopeptides
Sanofi Genzyme

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue